Identification and Tracking of Antiviral Drug Combinations
| Autor: | Jaewon Yang, Tanel Tenson, Svetlana Biza, Mona H. Fenstad, Marc P. Windisch, Magnar Bjørås, Rouan Yao, Gaily Kivi, Mart Ustav, Kirsti Løseth, Eva Zusinaite, Eva-Maria Tombak, Valentyn Oksenych, Denis E. Kainov, Svein Arne Nordbø, Kristiina Kurg, Astra Vitkauskienė, Per Arne Aas, Anu Planken, Hilde Lysvand, Nastassia Shtaida, Eunji Jo, Aleksandr Ianevski, Andres Männik, Evgeny Kulesskiy |
|---|---|
| Přispěvatelé: | Institute for Molecular Medicine Finland, University of Helsinki |
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Sofosbuvir Databases Pharmaceutical viruses lcsh:QR1-502 Hepacivirus medicine.disease_cause antiviral drug combinations lcsh:Microbiology 0302 clinical medicine antivirals Drug Discovery Neutralizing antibody 11832 Microbiology and virology biology broad-spectrum antivirals virus Lamivudine virus diseases Drug Synergism Enterovirus B Human 3. Good health Drug Combinations Infectious Diseases 030220 oncology & carcinogenesis Homoharringtonine ENTRY Coronavirus Infections medicine.drug Antiviral agents therapeutic use Drug therapy combination methods medicine.drug_class Hepatitis C virus Pneumonia Viral Antineoplastic Agents Antiviral Agents Article Virus Cell Line Betacoronavirus 03 medical and health sciences Virology medicine Humans Pandemics SARS-CoV-2 business.industry COVID-19 Antibodies Neutralizing COVID-19 Drug Treatment 030104 developmental biology Nelfinavir A549 Cells HIV-1 biology.protein 615.28 [udc] Antiviral drug business |
| Zdroj: | Viruses Volume 12 Issue 10 Viruses, Vol 12, Iss 1178, p 1178 (2020) Viruses, Basel, Switzerland : MDPI, 2020, vol. 12, no. 10, 1178, p. 1-15 |
| ISSN: | 1999-4915 |
| DOI: | 10.3390/v12101178 |
| Popis: | Combination therapies have become a standard for the treatment for HIV and hepatitis C virus (HCV) infections. They are advantageous over monotherapies due to better efficacy, reduced toxicity, as well as the ability to prevent the development of resistant viral strains and to treat viral co-infections. Here, we identify new synergistic combinations against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), echovirus 1 (EV1), hepatitis C virus (HCV) and human immunodeficiency virus 1 (HIV-1) in vitro. We observed synergistic activity of nelfinavir with convalescent serum and with purified neutralizing antibody 23G7 against SARS-CoV-2 in human lung epithelial Calu-3 cells. We also demonstrated synergistic activity of nelfinavir with EIDD-2801 or remdesivir in Calu-3 cells. In addition, we showed synergistic activity of vemurafenib with emetine, homoharringtonine, anisomycin, or cycloheximide against EV1 infection in human lung epithelial A549 cells. We also found that combinations of sofosbuvir with brequinar or niclosamide are synergistic against HCV infection in hepatocyte-derived Huh-7.5 cells, and that combinations of monensin with lamivudine or tenofovir are synergistic against HIV-1 infection in human cervical TZM-bl cells. These results indicate that synergy is achieved when a virus-directed antiviral is combined with another virus- or host-directed agent. Finally, we present an online resource that summarizes novel and known antiviral drug combinations and their developmental status. © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|